Porton Partners with Aojin for XDC Conjugate Drug Development

• Porton will offer comprehensive CDMO services for Aojin in the development and GMP production of XDC conjugate drugs.

• The collaboration targets dual IND filings in both China and the United States.

Porton Pharma Solutions, a prominent CDMO, has announced a strategic partnership with Aojin to support the development of XDC conjugate drugs. This collaboration encompasses pharmaceutical CMC research and GMP production, with the goal of filing dual IND applications in China and the United States.

With nearly two decades of experience in end-to-end contract manufacturing services, Porton has assembled a multidisciplinary project team. This team bridges expertise in small and large molecule technologies, ensuring seamless integration of drug substance and drug product development.

This agreement marks the beginning of a deep partnership between the two companies, focusing on advancing the XDC conjugate drug sector. Both organisations are committed to accelerating global innovation in this area, providing patients with earlier access to quality medicines.